-
Historical Archive
Italy-China agreement on food safety and medicines at the start
The electronic prescription of medicines can induce doctors to choose the least expensive ones and therefore constitute a favorable factor…
Leggi » -
Historical Archive
European justice: prescription drugs only in pharmacies
(AGI) - Rome, April 3. – "We must evaluate very positively some signs of the change in the image of biosimilar medicines both among…
Leggi » -
Historical Archive
Actelion launches share repurchase programme
Minister of Health, Renato Balduzzi, according to the director of Pascale, if there were no national health service, only a…
Leggi » -
Historical Archive
FederAnziani: 'The Regions volatilize 1.4 billion euros a year between waste and inefficiencies'
The face of an Indian woman in traditional dress and the link to a 'Glivec Information Center' where…
Leggi » -
Historical Archive
Standard costs: define the three reference Regions.
It is a black inverted triangle, accompanied by an invitation to report any side effects
Leggi » -
Historical Archive
Italian Pharmacovigilance continues like this, + 35% in 2012
From now on it will be able to produce the low cost Glivec, an anti-cancer product. Novartis, defeated: "This hinders research" It wants to be ...
Leggi » -
Historical Archive
Farmaceutica 2013, Federfarma data for the first nine months
37 revolutionary new molecules are coming. These are biotechnological molecules, monoclonal antibodies, based on biomarkers for hospital wards. I am…
Leggi » -
Historical Archive
The herd effect also exists in scientific research
"We were right." Thus Alfonso Misasi, national secretary of Federfarma comments on the decision of the Lazio TAR to suspend…
Leggi » -
Historical Archive
Ecm, Conte (Fnomceo): towards the individual training dossier for everyone.
Only two numbers, 2,600 against 175, are dollars and these numbers correspond to a month of treatment with…
Leggi » -
Historical Archive
Parallel exports in Europe: a worrying phenomenon, to the detriment of the Italian citizen and with no advantage for the pharmacy.
A US court has ruled that the patent protecting Pulmicort Respules, AstraZeneca's asthma drug in the United States…
Leggi »